BioAtla shares fall 25.75% intraday after strategic review and 70% workforce cut announced.

BioAtla (NASDAQ: BCAB) fell 25.75% intraday following announcements of a strategic review to monetize assets and a 70% workforce reduction. The board initiated a process to explore asset sales, licensing, or partnerships while cutting operating costs, signaling financial distress and uncertainty. The lack of assurance that these measures will yield transactions, coupled with significant job cuts, likely triggered investor pessimism, as the company emphasized retaining only essential staff and provided no timeline for updates. The restructuring underscores challenges in sustaining operations amid a volatile biotech landscape, aligning with the sharp intraday decline.